Indatuximab ravtansine

From WikiProjectMed
Jump to navigation Jump to search
Indatuximab ravtansine
Monoclonal antibody
TypeWhole antibody
SourceChimeric (mouse/human)
Clinical data
ATC code
  • none
CAS Number
  • none
 ☒NcheckY (what is this?)  (verify)

Indatuximab ravtansine (BT062) is an immunomodulator and antineoplastic antibody-drug conjugate.

It is the anti-CD138 chimerized MAb (nBT062)[1] linked to the maytansinoid DM4.[1]

It is being investigated as part of a treatment for multiple myeloma.[1]

Clinical trials

Multiple Myeloma

Preliminary data has been reported in 2013 from an early stage clinical trial in combination with Lenalidomide and Dexamethasone.[1] Follow up data reported "encouraging efficacy" in December 2014.[2]


As of December 2014, it is in clinical trials for triple negative metastatic breast cancer and metastatic urinary bladder cancer.[2]

Mechanism of action

CD138 (Syndecan-1) is highly overexpressed on various solid tumors and in hematological malignancies, and represents one of the most specific target antigens for identification of multiple myeloma (MM) cells.[1] The antibody part binds to CD138 on the target cells and then the DM4 kills the cell.

See also

  • ImmunoGen, more on DM1/DM4 and the linker used in Indatuximab ravtansine
  • Syndecan 1, the protein encoded by SDC1.